Citigroup Maintains Neutral on Phibro Animal Health, Lowers Price Target to $44
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Daniel Grosslight maintains Phibro Animal Health (NASDAQ:PAHC) with a Neutral and lowers the price target from $62 to $44.
Citigroup analyst Daniel Grosslight maintains Phibro Animal Health (NASDAQ:PAHC) with a Neutral and lowers the price target from $62 to $44.